LEXINGTON, Mass., May 17, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that several abstracts on its partnered programs have been accepted by the American Society of Clinical Oncology (ASCO) for presentation at its 2012 Annual Meeting being held from June 1-5 in Chicago, IL.
Data to be presented at the ASCO meeting include results from multiple studies of Erivedge™ (vismodegib, GDC-0449), a first-in-class oral medicine designed to selectively inhibit signaling in the Hedgehog pathway that is being developed by Roche and Genentech, under a collaboration agreement between Curis and Genentech, a member of the Roche Group. Curis' partner Debiopharm will also present Phase I data on Debio 0932, an orally-administered heat shock protein (Hsp90) inhibitor. Abstracts can be accessed at www.ASCO.org.
Presentations of interest are as follows:
| Friday, June 1, 2012, 11:05 AM – 11:25 AM | ||
| Location: | S406 | |
| Session Type: | Pre-Annual Meeting Seminar/New Drugs in Oncology | |
| Presentation Title: | Practical Information of Recently Approved Drugs for the Practicing Physician: vismodegib. | |
| Presenter: | Ramesh K. Ramanathan, MD | |
| Sunday, June 3, 2012, 8:00 AM – 12:00 PM | ||
| Location: | S Hall A2, Poster Board 36E | |
| Track: | Melanoma/Skin Cancers | |
| Session Type: | General Poster Session | |
| Presentation Title: | Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update. | |
| Presenter: | Aleksandar Sekulic, MD, PhD | |
| Abstract Number: | 8579 | |
| Sunday, June 3, 2012, 8:00 AM – 12:00 PM | ||
| Location: | S Hall A2, Poster Board 37C | |
| Track: | Melanoma/Skin Cancers | |
| Session Type: | General Poster Session | |
| Presentation Title: | Metastatic basal cell carcinoma: Differences in survival by site of spread. | |
| Presenter: | Margaret E. McCusker, M.D., M.S. | |
| Abstract Number: | 8585 | |
| Monday, June 4, 2012, 1:15 PM – 5:15 PM | ||
| Location: | E450a, Poster Board 14 | |
| Track: | Gastrointestinal (Noncolorectal) Cancer | |
| Session Type: | Poster Discussion Session (Display and Discussion) | |
| Presentation Title: | A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study. | |
| Presenter: | http://www.asco.org/portal/jsp/ascov2/generateSessionParticipationCOI.jsp?sessionParticipationId=75137">Daniel V. Catenacci, MD | |
| Abstract Number: | 4022 | |
| Monday, June 4, 2012, 4:15 PM – 4:30 PM | ||
| Location: | S406 | |
| Track: | Sarcoma | |
| Session Type: | Oral Abstract Session | |
| Presentation Title: | A first-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma. | |
| Presenter: | http://www.asco.org/portal/jsp/ascov2/generateSessionParticipationCOI.jsp?sessionParticipationId=71663">Mrinal M. Gounder | |
| Abstract Number: | 10004 | |
| Monday, June 4, 2012, 4:30 PM – 4:45 PM | ||
| Location: | S406 | |
| Track: | Sarcoma | |
| Session Type: | Oral Abstract Session | |
| Presentation Title: | GDC-0449 in patients with advanced chondrosarcomas: A French Sarcoma Group (FSG)/French and U.S. National Cancer Institutes phase II collaborative study. | |
| Presenter: | http://www.asco.org/portal/jsp/ascov2/generateSessionParticipationCOI.jsp?sessionParticipationId=69698">Antoine Italiano | |
| Abstract Number: | 10005 | |
| Saturday, June 2, 2012, 1:15 PM – 5:15 PM | ||
| Location: | S404, Poster Board 18 | |
| Track: | Developmental Therapeutics | |
| Session Type: | Poster Discussion Session (Display and Discussion) | |
| Presentation Title: | A phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors. | |
| Presenter: | Nicolas Isambert, MD | |
| Abstract Number: | 3026 | |
In addition to these presentations, Curis' abstract entitled "A phase Ib study of CUDC-101, a multi-targeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer," will be published electronically by ASCO. Curis intends to present the full results of this study at a medical conference in the second half of 2012.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com.
The Curis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11347